Biotech firm Cullgen snaps $40m in Series C round

Biotech firm Cullgen, a clinical-stage biopharmaceutical company, has bagged a total of $40 million in a Series C round, according to a company release. 

Related Keywords

Tokyo ,Japan ,California ,United States ,San Diego ,China ,Wuxi ,Jiangsu , ,Wuxi Capital Group ,Sincere Capital ,Voyagers Capital ,Wuxi Capital ,Bioventures Capital ,Heights Capital Management ,Octagon Capital ,South China Venture ,